Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 


PDE inhibitor
BML-PD140-0200 200 mg 76.00 USD
BML-PD140-1000 1 g 295.00 USD
Do you need bulk/larger quantities?
Replaces Prod. #: ALX-480-038

Potent, non-specific inhibitor of phosphodiesterases (IC50=2-50µM). More potent than theophylline at adenosine receptors. Accelerates conversion of mouse fibroblast cells into adipose cells.

Product Details

Purity:≥99% (HPLC)
Identity:Determined by NMR.
Appearance:White solid.
Solubility:Soluble in 100% ethanol, DMSO or methanol (warm, 50mg/ml); almost insoluble in water.
Shipping:Blue Ice
Long Term Storage:-20°C
Use/Stability:Store, as supplied at -20°C for up to 1 year. Store solutions at -20°C for up to 3 months.
Regulatory Status:RUO - Research Use Only
Please mouse over

Product Literature References

Exendin-4 stimulates autophagy in pancreatic β-cells via the RAPGEF/EPAC-Ca2+-PPP3/calcineurin-TFEB axis: F.P. Zummo, et al.; Autophagy 18, 799 (2022), Abstract;
PGE2-EP2/EP4 signaling elicits immunosuppression by driving the mregDC-Treg axis in inflammatory tumor microenvironment: D. Thumkeo, et al.; Cell Rep. 39, 110914 (2022), Abstract;
Effect of an antihypertensive hydrazine derivative on Ca2+ current of single frog cardiac cells: F. Scamps, et al.; Eur. J. Pharmacol. 244, 119 (1993), Abstract;
Isobutylmethylxanthine and other classical cyclic nucleotide phosphodiesterase inhibitors affect cAMP-dependent protein kinase activity: C. Tomes, et al.; Cell. Signal. 5, 615 (1993), Abstract;
Bemoradan--a novel inhibitor of the rolipram-insensitive cyclic AMP phosphodiesterase from canine heart tissue: J.B. Moore, Jr., et al.; Biochem. Pharmacol. 42, 679 (1991), Abstract;
Differential effects of Ro 20-1724 and isobutylmethylxanthine on the basal force of contraction and beta-adrenoceptor-mediated response in the rat ventricular myocardium: Y. Katano & M. Endoh; BBRC 167, 123 (1990), Abstract;
Psychomotor-stimulant effects of 3-isobutyl-1-methylxanthine: comparison with caffeine and 7-(2-chloroethyl) theophylline: V.L. Coffin and R.D. Spealman; Eur. J. Pharmacol. 170, 35 (1989), Abstract;
Methylxanthine inhibitors of phosphodiesterases: J.N. Wells & J.R. Miller; Methods Enzymol. 159, 489 (1988), Abstract;
Characterization of the A2 adenosine receptor labeled by [3H]NECA in rat striatal membranes: R.F. Bruns, et al.; Mol. Pharmacol. 29, 331 (1986), Abstract;
Selective inhibition of cyclic AMP and cyclic GMP phosphodiesterases of cardiac nuclear fraction: G.S. Ahluwalia & A.R. Rhoads; Biochem. Pharmacol. 31, 665 (1982), Abstract;
Induction of a transient elevation in intracellular levels of adenosine-3’,5’-cyclic monophosphate by chemotactic factors: an early event in human neutrophil activation: L. Simchowitz, et al.; J. Immunol. 124, 1482 (1980), Abstract;
Inhibition of growth of primary and metastatic Lewis lung carcinoma cells by the phosphodiesterase inhibitor isobutylmethylxanthine: P. Janik, et al.; Cancer Res. 40, 1950 (1980), Abstract;
Differentiation of 3T3-L2 fibroblasts into adipose cells in bromodeoxyuridine-suppressed cultures: T.R. Russell; PNAS 76, 4451 (1979), Abstract;
Allergic reactions, cyclic AMP and histamine release: P.S. Skov, et al.; Experientia 33, 965 (1977), Abstract;
Cyclic nucleotide phosphodiesterases of human and rat gastric mucosa: U. Klotz, et al.; Naunyn-Schmiedebergs Arch. Pharmacol. 296, 187 (1977), Abstract;
Methyl xanthine phosphodiesterase inhibitors behave as prostaglandin antagonists in a perfused rat mesenteric artery preparation: D.F. Horrobin, et al.; Prostaglandins 13, 33 (1977), Abstract;
Selective inhibition of cyclic nucleotide phosphodiesterases by analogues of 1-methyl-3-isobutylxanthine: G.L. Kramer, et al.; Biochemistry 16, 3316 (1977), Abstract;
Determination of theophylline in plasma by electron capture gas chromatography: H.A. Schwertner, et al.; Anal. Chem. 48, 1875 (1976), Abstract;
Concentration of adenosine 3’:5’-cyclic monophosphate in mouse pancreatic islets measured by a protein-binding radioassay: R.H. Cooper, et al.; Biochem. J. 134, 599 (1973), Abstract;
Effects of methylxanthines on adenosine 3’,5’-monophosphate and corticosterone in the rat adrenal: A. Peytremann, et al.; Endocrinology 92, 525 (1973), Abstract;
The mode of action of adenosine 3’:5’-cyclic monophosphate in mammalian islets of Langerhans. Effects of insulin secretagogues on islet-cell protein kinase activity: W. Montague & S.L. Howell; Biochem. J. 134, 321 (1973), Abstract;
Cyclic nucleotide phosphodiesterase activity in normal mouse pancreatic islets: S.J. Ashcroft, et al.; FEBS Lett. 20, 263 (1972), Abstract;
The role of adenosine 3':5'-cyclic monophosphate in the regulation of insulin release by isolated rat islets of Langerhans: W. Montague & J.R. Cook; Biochem. J. 122, 115 (1971), Abstract;
Adenosine 3':5'-cyclic monophosphate and insulin release: W. Montague & J.R. Cook; Biochem. J. 120, 9P (1970), Abstract;
Effects of xanthine derivatives on lipolysis and on adenosine 3',5'- monophosphate phosphodiesterase activity: J.A. Beavo, et al.; Mol. Pharmacol. 6, 597 (1970), Abstract;

Related Literature

Download as PDF

All new literature pieces